fulvestrant

The drug is indicated for the treatment of postmenopausal women with locally advanced or metastatic breast cancer that is estrogen receptor-positive. It is used both as monotherapy and in combination with palbociclib.

Form: solution for injection

ATC: L02BA03

Manufacturer: Dr. Reddy's Laboratories Limited, Manufacturing Unit - 9

The drug is intended for the treatment of postmenopausal women with locally advanced or metastatic breast cancer that has estrogen receptor-positive tumors. It is used both as monotherapy and in combination with palbociclib.

Form: solution for injection

ATC: L02BA03

Manufacturer: Wetter Pharma-Fertigungs GmbH & Co. KG (manufacturing, primary packaging, visual inspection, batch testing; description, identification by infrared (IR) spectroscopy, quantitative determination of fulvestrant by high-performance liquid chromatography (HPLC), degradation products by HPLC, volume of injectable solution in containers, functional testing of PFS, bacterial endotoxins, mechanical particulates (sub-visible particles), sterility, ethanol content by gas chromatography (GC), benzyl alcohol content by GC, benzyl benzoate content by GC; visual inspection; visual inspection, batch testing (sterility testing); manufacturing, primary packaging, visual inspection, batch testing; description, identification by infrared (IR) spectroscopy, quantitative determination of fulvestrant by high-performance liquid chromatography (HPLC), degradation products by HPLC, volume of injectable solution in containers, functional testing of PFS, bacterial endotoxins, mechanical particulates (sub-visible particles), sterility, ethanol content by gas chromatography (GC), benzyl alcohol content by GC, benzyl benzoate content by GC)

The drug is prescribed to women in postmenopause for the treatment of locally advanced or metastatic estrogen receptor-positive breast cancer. It may be used as monotherapy or in combination with palbociclib.

Form: solution for injection

ATC: L02BA03

Manufacturer: K.T. ROMFARM COMPANY S.R.L. (manufacturing and primary packaging of medicinal product; physico-chemical control and batch release; secondary packaging and biological and microbiological control of medicinal product)

The drug is prescribed to women in the postmenopausal period for the treatment of estrogen receptor-positive locally advanced or metastatic breast cancer. It may be used either as monotherapy or in combination with palbociclib.

Form: solution for injection

ATC: L02BA03

Manufacturer: EVER Pharma Jena GmbH (manufacturing of medicinal product, responsible for batch control and batch release; alternative unit for secondary packaging)

The drug is prescribed as monotherapy for the treatment of locally advanced or metastatic estrogen receptor-positive breast cancer in postmenopausal women. It is also used in combination with palbociclib for the treatment of appropriate breast cancer in women who have previously received endocrine therapy.

Form: solution for injection

ATC: L02BA03

Manufacturer: Laboratorios Echevarne, S.A. (manufacturer responsible for control of sterile products)